成都创新药龙头企业百利天恒，再冲港股IPO

Core Viewpoint - Chengdu-based innovative pharmaceutical leader Baillie Tianheng (688506.SH) is continuing its efforts to list H-shares in Hong Kong, as indicated by the recent decision to extend the validity period of the relevant resolutions [1][5] Group 1: Company Developments - On February 10, 2026, Baillie Tianheng's first extraordinary general meeting approved the extension of the resolution's validity period for issuing H-shares and listing [1] - The company previously announced on November 12, 2025, that it would delay its global offering and would not proceed according to the prospectus, postponing its planned listing on November 17, 2025 [1][5] - The delay in the global offering does not impact the company's current business operations, and the company is carefully evaluating the timeline for the global offering and listing [5] Group 2: Historical Context - Baillie Tianheng submitted its H-share listing application to the Hong Kong Stock Exchange on July 10, 2024, and subsequently resubmitted the application on January 21, 2025, and September 29, 2025 [5] - The company published its H-share hearing materials on October 22, 2025, to provide relevant information to the Hong Kong public and qualified investors [5] - As of October 2025, Baillie Tianheng's actual controller and chairman, Zhu Yi, was reported to have a net worth of 115 billion yuan, marking a significant rise of 44 positions compared to 2024 [5]